Skip to main content

Abbott Laboratories (ABT) Stock Analysis

Falling Knife setup

SellModerate Confidence

Healthcare · Medical Devices

Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $90.36 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: international sales (61.0%); Weak growth.

Abbott Laboratories discovers, manufactures, and sells diversified healthcare products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices — serving over 160 countries with approximately 115,000 employees. No... Read more

$90.36+18.1% A.UpsideScore 5.3/10#21 of 40 Medical Devices
Stop $87.58Target $106.78(analyst − 10%)A.R:R 3.3:1
Analyst target$118.64+31.3%25 analysts
$106.78our TP
$90.36price
$118.64mean
$143

Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $90.36 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: international sales (61.0%); Weak growth. Chart setup: Death cross, below all MAs, RSI 30, MACD bearish. Score 5.3/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 76d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Thesis

Rewards
Recent Analyst detected in news
Risks
Concentration risk — Geographic: international sales (61.0%)
Weak growth
Negative momentum

Key Metrics

P/E (TTM)25.6
P/E (Fwd)15.1
Mkt Cap$158.7B
EV/EBITDA13.5
Profit Mgn13.9%
ROE
Rev Growth7.8%
Beta0.78
Dividend2.76%
Rating analysts35

Quality Signals

Piotroski F7/9

Options Flow

P/C1.14bearish
IV38%normal
Max Pain$80-11.5% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHGeographicinternational sales61%
    10-K Item 1A: 'As a global healthcare company with sales outside of the U.S. making up approximately 61 percent of Abbott's net sales in 2025'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.0
Revenue Growth
4.4

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Ma Position
1.0
Rsi
3.0
Obv
10.0
Capitulation risk (RSI 30, below 200MA)Volume accumulation (rising OBV)Below 200-MA, MA slope -3.9%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
3.5
Value Rank
4.1
Quality Rank
7.5
GatesMomentum 2.8<4.5Death cross (50MA < 200MA)A.R:R 3.3 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.60EARNINGS PROXIMITY 76d clearSEMI CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
30 · Oversold
20D MA 50D MA 200D MADEATH CROSSSupport $90.29Resistance $103.19

Price Targets

$88
$107
A.Upside+18.2%
A.R:R3.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Momentum score 2.8/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-16 (76d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ABT stock a buy right now?

Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $90.36 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: international sales (61.0%); Weak growth. Chart setup: Death cross, below all MAs, RSI 30, MACD bearish. Prior stop was $87.58. Score 5.3/10, moderate confidence.

What is the ABT stock price target?

Take-profit target: $106.78 (+18.1% upside). Prior stop was $87.58. Stop-loss: $87.58.

What are the risks of investing in ABT?

Concentration risk — Geographic: international sales (61.0%); Weak growth; Negative momentum.

Is ABT overvalued or undervalued?

Abbott Laboratories trades at a P/E of 25.6 (forward 15.1). TrendMatrix value score: 6.4/10. Verdict: Sell.

What do analysts say about ABT?

35 analysts cover ABT with a consensus score of 4.0/5. Average price target: $119.

What does Abbott Laboratories do?Abbott Laboratories discovers, manufactures, and sells diversified healthcare products across four segments:...

Abbott Laboratories discovers, manufactures, and sells diversified healthcare products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices — serving over 160 countries with approximately 115,000 employees. No single customer is material; international sales represent approximately 61% of net sales in 2025.

Related stocks: BSX (Boston Scientific Corporation) · DXCM (DexCom, Inc.) · SYK (Stryker Corporation) · PHG (Koninklijke Philips N.V. NY Reg) · STE (STERIS plc (Ireland))